194 related articles for article (PubMed ID: 36682470)
1. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab.
Agrawal V; Pourhassan H; Tsai NC; Ngo D; Koller P; Malki MMA; Salhotra A; Ali H; Aribi A; Sandhu KS; Arslan S; Ball B; Otoukesh S; Amanam I; Artz A; Singh D; Becker PS; Stewart FM; Smith EP; Curtin P; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pullarkat V; Aldoss I
Transplant Cell Ther; 2023 May; 29(5):314-320. PubMed ID: 36682470
[TBL] [Abstract][Full Text] [Related]
2. Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.
Kayser S; Sartor C; Giglio F; Bruno A; Webster J; Chiusolo P; Saraceni F; Guerzoni S; Pochintesta L; Borlenghi E; Marconi G; Zacheo I; Cerrano M; Salutari P; Restuccia F; Abbenante M; Levis MJ; Schlenk RF; Papayannidis C
Haematologica; 2024 May; 109(5):1385-1392. PubMed ID: 38058184
[TBL] [Abstract][Full Text] [Related]
3. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Stelljes M; Liedtke M; Stock W; Gökbuget N; O'Brien SM; Jabbour E; Wang T; Liang White J; Sleight B; Vandendries E; Advani AS
Cancer; 2019 Jul; 125(14):2474-2487. PubMed ID: 30920645
[TBL] [Abstract][Full Text] [Related]
4. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537
[TBL] [Abstract][Full Text] [Related]
5. [Allogeneic hematopoietic stem cell transplantations for relapsed and refractory acute lymphoblastic leukemia following inotuzumab ozogamicin treatment].
Morishige S; Yamasaki Y; Oya S; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Mizushima Y; Nakashima O; Nagafuji K
Rinsho Ketsueki; 2022; 63(4):271-276. PubMed ID: 35491216
[TBL] [Abstract][Full Text] [Related]
6. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
[TBL] [Abstract][Full Text] [Related]
7. Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin).
McDonald GB; Freston JW; Boyer JL; DeLeve LD
Hepatology; 2019 Feb; 69(2):831-844. PubMed ID: 30120894
[TBL] [Abstract][Full Text] [Related]
8. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
Roeker LE; Kim HT; Glotzbecker B; Nageshwar P; Nikiforow S; Koreth J; Armand P; Cutler C; Alyea EP; Antin JH; Richardson PG; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2019 Jan; 25(1):137-144. PubMed ID: 30081073
[TBL] [Abstract][Full Text] [Related]
9. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain.
Torrent A; Morgades M; García-Calduch O; de Llano MPQ; Montesinos P; Navarro I; Hernández-Rivas JM; Bárez-García A; González-Campos J; Oiartzabal I; Valero M; Cervera M; Zudaire T; Albors-Ferreiro M; López-Godino O; Gil-Cortés C; Villalón L; Saldaña R; Ribera JM
Eur J Haematol; 2023 Sep; 111(3):485-490. PubMed ID: 37381686
[TBL] [Abstract][Full Text] [Related]
10. Defibrotide Shows Efficacy in the Prevention of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study.
Chalandon Y; Mamez AC; Giannotti F; Beauverd Y; Dantin C; Mahne E; Mappoura M; Bernard F; de Ramon Ortiz C; Stephan C; Morin S; Ansari M; Simonetta F; Masouridi-Levrat S
Transplant Cell Ther; 2022 Nov; 28(11):765.e1-765.e9. PubMed ID: 35953029
[TBL] [Abstract][Full Text] [Related]
11. Effect of Sirolimus levels between days 11 and 20 after allogeneic stem cell transplantation on the risk of hepatic sinusoidal obstruction syndrome.
Agrawal V; Ranganath P; Ervin KD; Schmidt CA; Cox EA; Nelson RP; Schwartz JE; Zaid MA; Abonour R; Robertson MJ; Brinda BJ; Griffin SP; Thakrar TC; Farag SS
Bone Marrow Transplant; 2021 Jan; 56(1):121-128. PubMed ID: 32623447
[TBL] [Abstract][Full Text] [Related]
12. Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation.
Giglio F; Xue E; Greco R; Lazzari L; Clerici DT; Lorentino F; Mastaglio S; Marktel S; Lupo-Stanghellini MT; Marcatti M; Corti C; Bernardi M; Piemontese S; Ciceri F; Peccatori J
Front Oncol; 2022; 12():933317. PubMed ID: 35785209
[TBL] [Abstract][Full Text] [Related]
13. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.
Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B
Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800
[TBL] [Abstract][Full Text] [Related]
14. Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy.
Lee J; Yoon JH; Kwag D; Lee JH; Kim TY; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Wook Lee J; Hak Lee S; Lee S
Ther Adv Hematol; 2021; 12():20406207211066176. PubMed ID: 34987745
[TBL] [Abstract][Full Text] [Related]
15. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD; O'Brien MM
Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
[TBL] [Abstract][Full Text] [Related]
16. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation.
Kiel PJ; Vargo CA; Patel GP; Rosenbeck LL; Srivastava S
Pharmacotherapy; 2012 May; 32(5):441-5. PubMed ID: 22499411
[TBL] [Abstract][Full Text] [Related]
17. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
18. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT.
Battipaglia G; Labopin M; Candoni A; Fanin R; El Cheikh J; Blaise D; Michallet M; Ruggeri A; Contentin N; Ribera JM; Stadler M; Sierra J; von dem Borne PA; Bloor A; Socié G; Nagler A; Mohty M
Bone Marrow Transplant; 2017 Apr; 52(4):592-599. PubMed ID: 28092357
[TBL] [Abstract][Full Text] [Related]
19. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia.
Metheny LL; Sobecks R; Cho C; Fu P; Margevicius S; Wang J; Ciarrone L; Kopp S; Convents RD; Majhail N; Caimi PF; Otegbeye F; Cooper BW; Gallogly M; Malek E; Tomlinson B; Gerds AT; Hamilton B; Giralt S; Perales MA; de Lima M
Blood Adv; 2024 Mar; 8(6):1384-1391. PubMed ID: 38170741
[TBL] [Abstract][Full Text] [Related]
20. [Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].
An LL; Zhao DF; Hou RF; Guan HH; Yan H; Lin YH; Tong CR; Wu T; Liu SY
Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):911-916. PubMed ID: 38185520
[No Abstract] [Full Text] [Related]
[Next] [New Search]
